Herald Regulatory News (HRI)

Herald Investment Trust plc (the "Company")

LEI: 213800U7G1ROCTJYRR70

Appointment of Andrew Joy as a non-executive director

Following a comprehensive selection process, conducted using a third-party search firm, Herald Investment Trust plc is pleased to announce the appointment of Andrew Joy as an independent non-executive director and chairman-designate of the Company with effect from 1 October 2022. Andrew is expected to succeed Tom Black as the Company's Chairman at the conclusion of the next AGM in April 2023 when Tom will stand down from the Board having completed nearly ten years of service. During the interim period, Tom will work closely with Andrew to ensure an orderly transition.

Andrew is currently chairman of The Biotech Growth Trust plc, a position he has held since July 2016 having joined the board in 2012 as a non-executive director. The Biotech Growth Trust has announced that Andrew is expected to retire from that role in July 2022. He is also a senior advisor of Stonehage Fleming, a leading international multi-family office, chairman of the investment committee of FPE Capital and is a trustee of several charities. For one of these charities, he chairs the investment committee of a £300 million endowment.

Andrew is highly regarded for his extensive knowledge of the financial sector and of the high-growth part of the smaller company sector. He was one of the founding partners of Cinven, a leading private equity firm investing in Europe and U.S. and has been chairman or director of numerous growth companies over the past 30 years. He is former chairman of the British Venture Capital and Private Equity Association and a director of the European Venture Capital Association.

There is no other information required to be disclosed under section 9.6.13 of the Listing Rules in respect of Andrew Joy.

20 June 2022

Enquiries

Sanne Fund Services (UK) Limited

Shilla Pindoria 020 3327 9720

Company Secretary